{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:03:57Z","timestamp":1760609037106},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T00:00:00Z","timestamp":1515110400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40265-017-0857-3","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T05:36:35Z","timestamp":1515130595000},"page":"203-214","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents"],"prefix":"10.1007","volume":"78","author":[{"given":"David R.","family":"Saxon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neda","family":"Rasouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,5]]},"reference":[{"key":"857_CR1","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med. 2014;370:1514\u201323.","journal-title":"N Engl J Med"},{"key":"857_CR2","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457\u201371.","journal-title":"N Engl J Med"},{"key":"857_CR3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-147-8-200710160-00182","volume":"147","author":"GA Diamond","year":"2007","unstructured":"Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147:578\u201381.","journal-title":"Ann Intern Med"},{"key":"857_CR4","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIR.0b013e3181d34114","volume":"121","author":"S Kaul","year":"2010","unstructured":"Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010;121:1868\u201377.","journal-title":"Circulation"},{"key":"857_CR5","unstructured":"Center for Drug Evaluation and Research. Guidance for industry diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [internet]. 2008. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf. Accessed 6 July 2017."},{"issue":"Suppl 2","key":"857_CR6","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.2337\/dc11-s202","volume":"34","author":"B Hirshberg","year":"2011","unstructured":"Hirshberg B, Raz I. Impact of the US Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011;34(Suppl 2):S101\u20136.","journal-title":"Diabetes Care"},{"key":"857_CR7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.2017.0029","volume":"317","author":"KJ Lipska","year":"2017","unstructured":"Lipska KJ, Krumholz HM. Is hemoglobin A1c the right outcome for studies of diabetes? JAMA. 2017;317:1017\u20138.","journal-title":"JAMA"},{"key":"857_CR8","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"FM Turnbull","year":"2009","unstructured":"Control Group, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288\u201398.","journal-title":"Diabetologia"},{"key":"857_CR9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-151-6-200909150-00137","volume":"151","author":"TN Kelly","year":"2009","unstructured":"Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:394\u2013403.","journal-title":"Ann Intern Med"},{"key":"857_CR10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"857_CR11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319\u201328.","journal-title":"N Engl J Med"},{"key":"857_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1615692","author":"SP Marso","year":"2017","unstructured":"Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723\u201332. https:\/\/doi.org\/10.1056\/nejmoa1615692 (Epub ahead of print 12 June 2017).","journal-title":"N Engl J Med."},{"key":"857_CR13","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"857_CR14","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854\u201365.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"857_CR15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1353\/pbm.2004.0071","volume":"47","author":"TB Schwartz","year":"2004","unstructured":"Schwartz TB, Meinert CL. The UGDP controversy: 34\u00a0years of contentious ambiguity laid to rest. Perspect Biol Med. 2004;47:564\u201374.","journal-title":"Perspect Biol Med"},{"key":"857_CR16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","volume":"40","author":"L Azoulay","year":"2017","unstructured":"Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care. 2017;40:706\u201314.","journal-title":"Diabetes Care"},{"key":"857_CR17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/dci17-0003","volume":"40","author":"MC Riddle","year":"2017","unstructured":"Riddle MC. Modern sulfonylureas: dangerous or wrongly accused? Diabetes Care. 2017;40:629\u201331.","journal-title":"Diabetes Care"},{"key":"857_CR18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","volume":"5","author":"O Vaccaro","year":"2017","unstructured":"Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5:887\u201397.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"857_CR19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/CIRCULATIONAHA.112.000678","volume":"128","author":"RG Bach","year":"2013","unstructured":"Bach RG, Brooks MM, Lombardero M, et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Circulation. 2013;128:785\u201394.","journal-title":"Circulation"},{"key":"857_CR20","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet Lond Engl. 2009;373:2125\u201335.","journal-title":"Lancet Lond Engl"},{"key":"857_CR21","unstructured":"US Food and Drug Administration. Rosiglitazone-containing diabetes medicines: drug safety communication\u2014FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) [internet]. 2015. https:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm477601.htm. Accessed 7 July 2017."},{"key":"857_CR22","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet Lond Engl. 2005;366:1279\u201389.","journal-title":"Lancet Lond Engl"},{"key":"857_CR23","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321\u201331.","journal-title":"N Engl J Med"},{"key":"857_CR24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"857_CR25","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579\u201388.","journal-title":"Circulation"},{"key":"857_CR26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327\u201335.","journal-title":"N Engl J Med"},{"key":"857_CR27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"key":"857_CR28","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"key":"857_CR29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"857_CR30","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","DOI":"10.1056\/NEJMoa1607141"},{"key":"857_CR31","unstructured":"Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk [internet]. 2017. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2017\/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-23052017.html. Accessed 7 July 2017."},{"key":"857_CR32","unstructured":"Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO trial for ITCA 650, an investigational therapy for type 2 diabetes [internet]. 2016. https:\/\/www.intarcia.com\/media\/press-releases\/2016-may-6-cardiovascular-safety.html. Accessed 7 July 2017."},{"key":"857_CR33","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"857_CR34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMe1607413","volume":"375","author":"JR Ingelfinger","year":"2016","unstructured":"Ingelfinger JR, Rosen CJ. Cardiac and renovascular complications in type 2 diabetes\u2013is there hope? N Engl J Med. 2016;375:380\u20132.","journal-title":"N Engl J Med"},{"key":"857_CR35","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115\u201322.","journal-title":"Diabetes Care"},{"key":"857_CR36","unstructured":"US Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes [internet]. 2016. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm531517.htm. Accessed 7 July 2017."},{"key":"857_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u2013657. https:\/\/doi.org\/10.1056\/nejmoa1611925 (Epub ahead of print 12 June 2017).","journal-title":"N Engl J Med."},{"key":"857_CR38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"J-L Chiasson","year":"2003","unstructured":"Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486\u201394.","journal-title":"JAMA"},{"key":"857_CR39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","volume":"25","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10\u20136.","journal-title":"Eur Heart J"},{"key":"857_CR40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","volume":"5","author":"RR Holman","year":"2017","unstructured":"Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:877\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"857_CR41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71\u201386.","journal-title":"BMJ"},{"key":"857_CR42","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.jacc.2011.10.824","volume":"58","author":"SC Smith","year":"2011","unstructured":"Smith SC, Benjamin EJ, Bonow RO, et al. AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"857_CR43","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.116.023164","volume":"134","author":"D Capodanno","year":"2016","unstructured":"Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation. 2016;134:1579\u201394.","journal-title":"Circulation"},{"key":"857_CR44","doi-asserted-by":"crossref","unstructured":"ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA. 1992;268:1292\u20131300.","DOI":"10.1001\/jama.268.10.1292"},{"key":"857_CR45","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"H Ogawa","year":"2008","unstructured":"Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134\u201341.","journal-title":"JAMA"},{"key":"857_CR46","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.","journal-title":"BMJ"},{"key":"857_CR47","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s11606-009-1095-5","volume":"24","author":"PR Hebert","year":"2009","unstructured":"Hebert PR, Schneider WR, Hennekens CH. Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment. J Gen Intern Med. 2009;24:1248\u201350.","journal-title":"J Gen Intern Med"},{"key":"857_CR48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","volume":"135","author":"Y Saito","year":"2016","unstructured":"Saito Y, Okada S, Ogawa H, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes: 10-year follow-up of a randomized controlled trial. Circulation. 2016;135:659\u201370.","journal-title":"Circulation"},{"key":"857_CR49","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/dc10-0555","volume":"33","author":"M Pignone","year":"2010","unstructured":"Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. Diabetes Care. 2010;33:1395\u2013402.","journal-title":"Diabetes Care"},{"key":"857_CR50","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.2337\/dc17-S012","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association. 9. Cardiovascular disease and risk management. Diabetes Care. 2017;40:S75\u201387.","journal-title":"Diabetes Care"},{"key":"857_CR51","unstructured":"ASCEND: a study of cardiovascular events iN Diabetes [internet]. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00135226. Accessed 7 July 2017."},{"key":"857_CR52","unstructured":"A study to assess the efficacy and safety of enteric-coated acetylsalicylic acid in patients at moderate risk of cardiovascular disease (ARRIVE) [internet]. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00501059. Accessed 7 July 2017."},{"key":"857_CR53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1745-6215-8-21","volume":"8","author":"G Berardis De","year":"2007","unstructured":"De Berardis G, Sacco M, Evangelista V, et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.","journal-title":"Trials"},{"key":"857_CR54","doi-asserted-by":"crossref","unstructured":"ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36:555\u201364.","DOI":"10.1016\/j.cct.2013.09.014"},{"key":"857_CR55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1\u201345.","journal-title":"Circulation"},{"key":"857_CR56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet Lond Engl. 2004;364:685\u201396.","journal-title":"Lancet Lond Engl"},{"key":"857_CR57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"PM Kearney","year":"2008","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet Lond Engl. 2008;371:117\u201325.","journal-title":"Lancet Lond Engl"},{"key":"857_CR58","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Lond Engl. 2010;376:1670\u201381.","journal-title":"Lancet Lond Engl"},{"key":"857_CR59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet Lond Engl. 2002;360:7\u201322.","journal-title":"Lancet Lond Engl"},{"key":"857_CR60","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins R, Armitage J, Parish S, et al. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet Lond Engl. 2003;361:2005\u201316.","journal-title":"Lancet Lond Engl"},{"key":"857_CR61","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","volume":"316","author":"R Chou","year":"2016","unstructured":"Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:2008\u201324.","journal-title":"JAMA"},{"key":"857_CR62","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"857_CR63","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00125-006-0177-8","volume":"49","author":"S Lally","year":"2006","unstructured":"Lally S, Tan CY, Owens D, et al. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia. 2006;49:1008\u201316.","journal-title":"Diabetologia"},{"key":"857_CR64","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/dom.12909","volume":"19","author":"LA Leiter","year":"2017","unstructured":"Leiter LA, Zamorano JL, Bujas-Bobanovic M, et al. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: a sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017;19:989\u201396.","journal-title":"Diabetes Obes Metab"},{"key":"857_CR65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","volume":"4","author":"N Sattar","year":"2016","unstructured":"Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4:403\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"857_CR66","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","volume":"123","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799\u2013810.","journal-title":"Circulation"},{"key":"857_CR67","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"CA Emdin","year":"2015","unstructured":"Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603\u201315.","journal-title":"JAMA"},{"key":"857_CR68","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet Lond Engl. 2016;387:957\u201367.","journal-title":"Lancet Lond Engl"},{"key":"857_CR69","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10\u2014should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922\u201344.","journal-title":"J Hypertens"},{"key":"857_CR70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11886-015-0590-z","volume":"17","author":"S Wharton","year":"2015","unstructured":"Wharton S, Serodio KJ. Next generation of weight management medications: implications for diabetes and CVD risk. Curr Cardiol Rep. 2015;17:35.","journal-title":"Curr Cardiol Rep"},{"key":"857_CR71","unstructured":"Osborne S. Orexigen pulls the plug on post-marketing cardiovascular trial [internet]. 2016. http:\/\/seekingalpha.com\/article\/3965636-orexigen-pulls-plug-post-marketing-cardiovascular-trial. Accessed 7 July 2017."},{"key":"857_CR72","unstructured":"A study to evaluate the effect of long-term treatment with BELVIQ (lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes mellitus in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors [internet]. 2017. https:\/\/www.clinicaltrials.gov\/show\/NCT02019264. Accessed 7 July 2017."},{"key":"857_CR73","unstructured":"Vivus announces operational update [internet]. 2017. http:\/\/ir.vivus.com\/releasedetail.cfm?ReleaseID=904060. Accessed 7 July 2017."},{"key":"857_CR74","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315:990\u20131004.","journal-title":"JAMA"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0857-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0857-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0857-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T01:46:08Z","timestamp":1570585568000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0857-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,5]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["857"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0857-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,5]]}}}